Healthcare >> Analyst Interviews >> September 29, 2003

New Approaches In Drug Delivery: Matthew Kaplan – Punk Ziegel & Co

MATTHEW L. KAPLAN is Managing Director, Health Care Group - Equity Research, at Ladenburg Thalmann. He focuses on therapeutic companies, cardiovascular and drug delivery. Mr. Kaplan spent 13 years as a Biotechnology Analyst at PZ & Co., Evolution Capital and The Carson Group. He has six years of research experience with the Albert Einstein College of Medicine/Montefiore Hospital Department of Cardiology and has co-authored numerous articles on gene regulation in the heart. Mr. Kaplan holds a B.S. in biology from the University of Michigan. Profile
TWST: Matt, what's going on in this space from a market perspective so

far this year?

Mr. Kaplan: I think fundamentally there are a couple of things to

mention. A number of companies have